Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M UNGER

Showing results (461-470 of 604) with videos related to

Pageof 61
Sort By:
JCO Clinical Cancer Informatics|April 21, 2023
Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG)Shing M Lee, Weijia Fan, Aijin Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2000
Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809R I Fisher, B W Dana, M LeBlanc, et al.
Journal of the National Cancer Institute|February 25, 2021
Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase InhibitorsDawn L Hershman, Alfred I Neugut, Anna Moseley, et al.
Sleep Medicine|May 1, 2012
DTI reveals hypothalamic and brainstem white matter lesions in patients with idiopathic narcolepsyK Menzler, M Belke, M M Unger, et al.
JAMA Oncology|January 1, 2016
Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate CancerDawn L Hershman, Joseph M Unger, Jason D Wright, et al.
Plos One|October 22, 2014
Tenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate cancer targeting using human xenograft tumors in miceJaneen H Trembley, Gretchen M Unger, Vicci L Korman, et al.
Blood|May 10, 2003
A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911Oliver W Press, Joseph M Unger, Rita M Braziel, et al.
In Vitro Cellular & Developmental Biology. Animal|March 6, 2009
Lectin binding patterns reflect the phenotypic status of in vitro chondrocyte modelsS Toegel, V E Plattner, S Q Wu, et al.
JAMA Network Open|November 11, 2022
Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor-Related Joint Pain: A Randomized Clinical TrialDawn L Hershman, Joseph M Unger, Heather Greenlee, et al.
In Vivo (Athens, Greece)|December 28, 2000
Tumor blood supply and tumor localization by adoptively transferred IL-2 activated natural killer cellsU Nannmark, M E Hokland, R Agger, et al.
Pageof 61

Showing results (461-470 of 604) with videos related to

Sort By:
Pageof 61
JCO Clinical Cancer Informatics|April 21, 2023
Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG)Shing M Lee, Weijia Fan, Aijin Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2000
Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809R I Fisher, B W Dana, M LeBlanc, et al.
Journal of the National Cancer Institute|February 25, 2021
Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase InhibitorsDawn L Hershman, Alfred I Neugut, Anna Moseley, et al.
Sleep Medicine|May 1, 2012
DTI reveals hypothalamic and brainstem white matter lesions in patients with idiopathic narcolepsyK Menzler, M Belke, M M Unger, et al.
JAMA Oncology|January 1, 2016
Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate CancerDawn L Hershman, Joseph M Unger, Jason D Wright, et al.
Plos One|October 22, 2014
Tenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate cancer targeting using human xenograft tumors in miceJaneen H Trembley, Gretchen M Unger, Vicci L Korman, et al.
Blood|May 10, 2003
A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911Oliver W Press, Joseph M Unger, Rita M Braziel, et al.
In Vitro Cellular & Developmental Biology. Animal|March 6, 2009
Lectin binding patterns reflect the phenotypic status of in vitro chondrocyte modelsS Toegel, V E Plattner, S Q Wu, et al.
JAMA Network Open|November 11, 2022
Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor-Related Joint Pain: A Randomized Clinical TrialDawn L Hershman, Joseph M Unger, Heather Greenlee, et al.
In Vivo (Athens, Greece)|December 28, 2000
Tumor blood supply and tumor localization by adoptively transferred IL-2 activated natural killer cellsU Nannmark, M E Hokland, R Agger, et al.
Pageof 61